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cyclophilin B that causes hyperelastosis cutis in
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Background: Hyperelastosis cutis is an inherited autosomal recessive connective tissue disorder. Affected horses are
characterized by hyperextensible skin, scarring, and severe lesions along the back. The disorder is caused by a
mutation in cyclophilin B.
Results: The crystal structures of both wild-type and mutated (Gly6->Arg) horse cyclophilin B are presented. The
mutation neither affects the overall fold of the enzyme nor impairs the catalytic site structure. Instead, it locally
rearranges the flexible N-terminal end of the polypeptide chain and also makes it more rigid.
Conclusions: Interactions of the mutated cyclophilin B with a set of endoplasmic reticulum-resident proteins must
be affected.
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Hyperelastosis cutis (HC) or Hereditary equine regional
dermal asthenia (HERDA), a degenerative skin disease in
Quarter horses has been reported since 1978, in which
the skin is described as hyperelastic, fragile and thin,
with slow-healing wounds characterized by atrophic
scars [1]. Lesions may be single or multiple, and are
most commonly seen on the dorsum, although they may
also occur on the legs [1]. Foals affected with HC rarely
show symptoms at birth, but develop seromas, hemato-
mas, and ulcerations primarily along the dorsal aspect
that progressively worsen in frequency and severity with
age. Many cases are not identified until the horses have
a saddle on their backs, and lesions are most commonly
found along the dorsal aspect, coincident with where the
saddle would rest. The majority of affected horses are* Correspondence: hpb@shcc.org
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reproduction in any medium, provided the oreuthanized. Published case reports describing HC have
compared the disease to Ehlers–Danlos syndrome [2].
A missense mutation in cyclophilin B (CypB) has been
identified and pointed to a causal candidate gene for HC
[3]. The mutation alters a glycine residue that has been
conserved across vertebrates. The mutation is homozy-
gous in affected horses. Screening of control Quarter
horses indicates a 3.5% carrier frequency [3]. CypB is a
peptidyl prolyl cis-trans-isomerase (PPIase) found in the
endoplasmic reticulum (ER) [4,5]. CypB plays a signifi-
cant role in the triple helix folding of collagen [6]. It
catalyzes the slow cis-trans isomerization of multiple pro-
line residues in the collagen chain. Severe osteogenesis
imperfecta (brittle bone disease) was observed in patients
with mutations in CypB [7] or in CypB-deficient mice [8].
The more prevalent autosomal dominant forms of
osteogenesis imperfecta are caused by primary defects in
type I collagen, whereas autosomal recessive forms are
caused by deficiency of proteins like CypB which interact
with type I procollagen during post-translational mod-
ification and/or folding [9]. CypB forms a complex with
prolyl 3-hydroxylase and cartilage-associated protein [10].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Crystal structures of wild-type and HC CypB. A. Cα ribbon presentation of horse wild-type (green) and HC (red) CypB. Chain
displacement is observed within the N-terminal tail (residues from Ala(−1) to Pro7) B. Superimposed active site of horse wild-type (green), HC
(red) and human (yellow; PDB: 1CYN [18]) CypB. Cyclosporin A is shown as ribbon (blue), which is a part of the complex with human CypB.
Sidechains of residues that contribute to the binding of cyclosporin A are shown as sticks. C. Electron density maps for wild-type and HC CypB
molecules calculated using 2Fo-Fc coefficients contoured at 1.0σ and shown in gray. D. Refined residue occupancy values of the N-terminal
sequence for the wild-type (green) and HC (red) CypB models. E. Refined Cα B factors of the N-termini for the wild-type (green) and HC (red)
CypB models. F. Stereo pair of superimposed structures of horse wild-type CypB (green), HC CypB (magenta) and the human CypB (yellow)
complexed with the P-domain of calmegin [14] (white).
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thesis [11]. Like other ER chaperones and foldases, CypB
is involved in formation of transient multi-protein com-
plexes that facilitate individual protein activities on nas-
cent chains [12]. The binding partners of CypB are PDI
(protein disulfide-isomerase), HSP47 (47kDa heat shock
protein), BiP (binding immunoglobulin protein), GRp94
(94 kDa glucose-regulated protein), ERp72 (ER resident
protein 72), ERp5 (ER protein 5), calreticulin, calnexin
[13].
Here, we present the crystal structures of recombi-
nantly produced wild-type and HC-mutant CypB from
the horse. The only difference is within the N-terminal
labile end that plays a role in complex formation with
other ER-resident chaperones and foldases.
Results
Overall structure
Wild-type and HC CypB were crystallized using the
same crystallization conditions in space group C2 with
one molecule per asymmetric unit. Therefore, all differ-
ences observed in the atomic models are attributable to
the HC mutation (Gly6->Arg). Human and horse CypB
share 96% sequence identity and the crystal structures
are near identical (rmsd < 0.46 Å for 178 equivalent Cα
positions, human CypB PDB: 3ICH [14]). The HC CypB
molecule demonstrates the same overall structure with
the exception for the very short N-terminal region that
precedes the mutation site (Figure 1A) (rmsd = 1.31 Å
for 8 equivalent Cα positions). The catalytic site remains
undisturbed in the HC CypB molecule (Figure 1B).
N-terminal region
Strong electron density is observed for all N-terminal
residues of HC CypB (Figure 1C). While slightly weaker,
electron density in this region was sufficient to unam-
biguously model the wild-type structure. In a previously
reported high-resolution structure of human CypB the
first three residues are disordered [14]. The presence of
two recombinantly added amino acids (Ala-Met) preced-
ing the natural sequence in our constructs of both HC
and normal CypB accounts for a partial stabilization of
the N-terminal segment via charge/polar contacts of Ala
(−1) with His133 of a neighbor molecule (a zinc ion
coordinates this interaction) and hydrophobic environ-
ment for Met0 formed by residues Met68, Ala108 and
Phe120 of the adjacent molecule. The conformations of
N-terminal sequences are only partially populated as
revealed by the difference map, therefore variable occu-
pancies were allowed for residues ranging from Ala(−1)
to Lys(5) (Figure 1D). Moreover, weak difference dens-
ities from Fo-Fc maps in the vicinity of Ala(−1) to Lys5
suggest that the structure might adopt alternate confor-
mations in this region, but only one conformation couldbe modeled. The N-terminal sequences appear to be the
most flexible, with refined B-factors higher than average
(Figure 1E). The Gly6->Arg mutation in HC CypB
appears to endow greater stability in the N-terminal
region, as residues Ala(−1) to Arg6 in the HC mutant
structure have higher occupancy values for residues
(~0.7 vs. ~0.5 for wild-type) and significantly lower
refined B-factors (5–12 Å2 vs. 9–20 Å2 for wild-type).
Thus, the Gly6->Arg mutation causes significant change
in the structure (up to 4.2 Å shift for the backbone at
residue Lys5), with the wild-type side chain density of
Lys5 being partially occupied by HC Arg6, and the flexi-
bility of the N-terminal region sharply reduced.
P-domain interaction interface
The recently reported crystal structure of human CypB
complexed with the proline-rich P-domain of calmegin
reveals that the binding involves the N-terminal region of
cyclophilin and the surfaces of CypB and P-domain are
complementary [14]. That binding site is on the opposite
side of CypB than the peptidyl prolyl cis-trans-isomerase
activity site. The N-terminal region forms part of the P-
domain binding interface, contributing several hydrogen
bonds. In HC CypB, the binding interface is altered: CypB
overlaps with the P-domain, when superimposed, such
that it could adversely affect binding (Figure 1F).
Discussion
Our structures suggest a molecular rationale for the
disease phenotype of the HC mutation in CypB of the
American quarter horse. Evidence is accumulating that
the N-terminal region of CypB interacts not only with
calreticulin, but also with ER chaperones and foldases.
Indeed, we have recently shown an altered interaction
between HC CypB with the P-domain of calreticulin and
loss of complex formation with lysyl hydroxylase 1 [15].
Interactions of CypB with ERp72 and GRp94 also re-
quire the N-terminal tail as confirmed by NMR experi-
ments with the strongest chemical shifts observed for
residues Lys3, Lys4, Lys5, Lys8 [13]. The same mode of
CypB binding might be valid for BiP, PDI, ERp5 and cal-
reticulin, where a polyacidic sequence similar to the one
located in ERp72 was recognized [13]. The Gly6->Arg
mutation in HC CypB has two consequences; first, it
adds an additional positive charge to the polybasic
stretch, which is involved in the binding of the polyaci-
dic region in calreticulin and thus can enhance the affin-
ity, second, it significantly distorts the geometry and
flexibility of the N-terminal tail and thus can slow down,
limit or even eliminate binding-competent conforma-
tions. As seen in Figure 1F a conformation of the HC
CypB N-terminal tail is likely incompatible with P-
domain interactions. Nevertheless, HC CypB binds the
P-domain of calreticulin, but shows aberrant kinetics
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are observed for both association and dissociation [15].
The two consequences of the mutation in HC CypB
have a synergistic effect on the overall P-domain bind-
ing. Binding of lysyl hydroxylase 1 to HC CypB is fully
abolished [15], which establishes a more important role
of the N-terminal tail and a stronger requirement for the
N-terminal tail flexibility. Three lysine residues preced-
ing the mutated glycine residue can be involved in Nε
acetylation, which was recently reported for CypB [16].
The mutation might affect acetylation and this could
also cause changes in the repertoire and mode of inter-
actions with other proteins.
Conclusion
Hyperelastosis cutis is a connective tissue disorder caused
by the Gly6->Arg mutation in cyclophilin B. The high
resolution structures of the recombinant wild-type and
mutated horse cyclophilin B provide evidence that the
active enzymatic site is undisturbed and suggesting that
the disease phenotype is caused by changes in the structureTable 1 Summary of data collection and refinement statistics
W
Data collection
Space group
a, b, c (Å)
α, β, γ (°)
Resolutiona (Å)
Measured reflectionsa
Unique reflectionsa
Redundancya
Completenessa (%)
Matthews coefficient (Å3 Da-1)
Solvent fraction (%)
I/σIa
Wilson plot B-factor (Å2)
Rmerge
a (%)
Refinement
R-factor (%)
Rfree (%)
Protein/solvent atomsb
Rmsd. of bond lengths (Å)
Rmsd. of bond angles (°)
Average B valuec (Å2)
Ramachandran favored/allowed/outliers (%)
MolProbity score [22] 0
aValues in parentheses are for the highest resolution shell.
bExcluding hydrogen atoms.
cValues in parentheses are for macromolecule atoms.and flexibility of the N-terminal tail, altering interactions
with other ER-resident chaperones and foldases.
Methods
Expression and purification of wild-type and HC
cyclophilin B
The wild-type and HC CypB were recombinantly produced
in bacteria and purified as described [15].
Crystallization and datacollection
The purified recombinant wild-type and HC horse CypB
were dialyzed against 10mM Tris/HCl, pH 7.2, and
concentrated to about 6 mg/ml using an Amicon spin
concentrator. The proteins were crystallized at room
temperature using the hanging drop vapor diffusion
method. For crystallization, 1 μl of the peptide solution
was mixed with 1 μl of the reservoir solution containing
0.1M MES, 10mM ZnCl2, 10% glycerol and 28% poly-
ethylene glycol monomethyl ether 550, pH 6.5. The crys-
tals of hexagonal shape appeared within 2–5 days. The
crystals were directly frozen in liquid nitrogen since theild-type CypB (4FRU) HC CypB (4FRV)
C2 C2
64.9, 44.1, 60.6 64.8, 44.2, 60.1
90, 95.2, 90 90, 95.5, 90
16.4-1.1 (1.16-1.10) 16.3-1.1 (1.16-1.10)
208,598 (10,718) 206,447 (10,544)
62,397 (5,316) 61,849 (5,304)
3.3 (2.0) 3.3 (2.0)
90.4 (53.4) 90.2 (53.4)
2.1 2.1
41.8 41.1
9.8 (3.9) 12.4 (4.2)
4.2 4.4
7.8 (27.2) 5.2 (24.2)
11.6 11.9
13.9 13.8
1472/300 1481/293
0.007 0.007
1.30 1.29
10.0 (7.8) 10.2 (7.2)
97.8 / 2.2 / 0 97.8 / 2.2 / 0
.64 (100th percentile) 0.90 (99th percentile)
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protectant condition.
Data collection was performed using crystals flash-frozen
to 100K on the “NOIR-1” detector system at the Molecular
Biology Consortium Beamline 4.2.2 of the Advanced Light
Source, Lawrence Berkeley National Laboratory.
Crystal structure determination
The images collected were indexed, integrated and
scaled using MOSFLM and SCALA from the CCP4 suite
[17]. The AMORE program was used within the CCP4
suite [17] to find initial molecular replacement solutions.
A crystal structure of human cyclophilin B (PDB: 1CYN)
[18] was used as a search model. A single outstanding
solution was generated by AMORE. Iterative cycles of
model correction and refinement were performed using
COOT [19] and PHENIX [20], respectively. Hydrogens
were added and refined in riding positions. B factors of
all atoms except hydrogens were refined anisotropically.
Seven alternative side chain conformations were built
for the models of both the wild-type and HC CypB. Two
zinc ions were found to be involved in crystal contacts.
Two short fragments of polyethylene glycol monomethyl
ether 550 were fitted near each model. The quality of
the models was assessed with program MolProbity
(http://molprobity.biochem.duke.edu/). Data collection and
refinement statistics are summarized in Table 1. Figures
were generated with programs PyMOL (http://www.
pymol.org) and CCP4MG [21].
Availability of supporting data
The atomic coordinates and structure factors have been
deposited with the protein Data Bank (PDB: 4FRU for
wild-type and 4FRV for HC CypB).Abbreviations
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